Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiegman, C. H.
Right arrow Articles by Kuipers, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiegman, C. H.
Right arrow Articles by Kuipers, F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 52:1081-1089, 2003
© 2003 by the American Diabetes Association, Inc.

Hepatic VLDL Production in ob/ob Mice Is Not Stimulated by Massive De Novo Lipogenesis but Is Less Sensitive to the Suppressive Effects of Insulin

Coen H. Wiegman1, Robert H.J. Bandsma1, Margriet Ouwens2, Fjodor H. van der Sluijs1, Rick Havinga1, Theo Boer1, Dirk-Jan Reijngoud1, Johannes A. Romijn3, and Folkert Kuipers1

1 Groningen University Institute for Drug Exploration, Center for Liver, Digestive and Metabolic Diseases, Department of Pediatrics, University Hospital Groningen, Groningen, the Netherlands
2 Department of Molecular Cell Biology, University Hospital Leiden, Leiden, the Netherlands
3 Department of Endocrinology, University Hospital Leiden, Leiden, the Netherlands

Type 2 diabetes in humans is associated with increased de novo lipogenesis (DNL), increased fatty acid (FA) fluxes, decreased FA oxidation, and hepatic steatosis. In this condition, VLDL production is increased and resistant to suppressive effects of insulin. The relationships between hepatic FA metabolism, steatosis, and VLDL production are incompletely understood. We investigated VLDL-triglyceride and -apolipoprotein (apo)-B production in relation to DNL and insulin sensitivity in female ob/ob mice. Hepatic triglyceride (5-fold) and cholesteryl ester (15-fold) contents were increased in ob/ob mice compared with lean controls. Hepatic DNL was increased ~10-fold in ob/ob mice, whereas hepatic cholesterol synthesis was not affected. Basal rates of hepatic VLDL-triglyceride and -apoB100 production were similar between the groups. Hyperinsulinemic clamping reduced VLDL-triglyceride and -apoB100 production rates by ~60% and ~75%, respectively, in lean mice but only by ~20% and ~20%, respectively, in ob/ob mice. No differences in hepatic expression of genes encoding apoB and microsomal triglyceride transfer protein were found. Hepatic expression and protein phosphorylation of insulin receptor and insulin receptor substrate isoforms were reduced in ob/ob mice. Thus, strongly induced hepatic DNL is not associated with increased VLDL production in ob/ob mice, possibly related to differential hepatic zonation of apoB synthesis (periportal) and lipid accumulation (perivenous) and/or relatively low rates of cholesterogenesis. Insulin is unable to effectively suppress VLDL-triglyceride production in ob/ob mice, presumably because of impaired insulin signaling.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
J. N. van der Veen, R. Havinga, V. W. Bloks, A. K. Groen, and F. Kuipers
Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor {alpha}
J. Lipid Res., February 1, 2007; 48(2): 337 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
B. H.-J. Chang, L. Li, A. Paul, S. Taniguchi, V. Nannegari, W. C. Heird, and L. Chan
Protection against Fatty Liver but Normal Adipogenesis in Mice Lacking Adipose Differentiation-Related Protein
Mol. Cell. Biol., February 1, 2006; 26(3): 1063 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. R. Goudriaan, M. A. M. den Boer, P. C. N. Rensen, M. Febbraio, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol
CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance
J. Lipid Res., October 1, 2005; 46(10): 2175 - 2181.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. R. Tovar, I. Torre-Villalvazo, M. Ochoa, A. L. Elias, V. Ortiz, C. A. Aguilar-Salinas, and N. Torres
Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats
J. Lipid Res., September 1, 2005; 46(9): 1823 - 1832.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. Grefhorst, J. Hoekstra, T. G. J. Derks, D. M. Ouwens, J. F. W. Baller, R. Havinga, L. M. Havekes, J. A. Romijn, and F. Kuipers
Acute hepatic steatosis in mice by blocking {beta}-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production
Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G592 - G598.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Sato, K. Kobayashi, T. Inoguchi, N. Sonoda, M. Imamura, N. Sekiguchi, N. Nakashima, and H. Nawata
Adenovirus-Mediated High Expression of Resistin Causes Dyslipidemia in Mice
Endocrinology, January 1, 2005; 146(1): 273 - 279.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.